
CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,



(I),

in which

either

X_1 is CR_1 or N;

X_3 is CR_3 or N;

X_4 is CR_4 or N;

X_5 is CR_5 or N;

wherein at least one of X_1, X_3, X_4 and X_5 is N and not more than 2 of X_1, X_3, X_4 and X_5 are N;

or

X_1 is CR_1 or N;

X_3 is CR_3, N or S;

X_4 is a bond;

X_5 is CR_5, N or S;

wherein at least one of X_1, X_3 and X_5 is N or S, not more than 2 of X_1, X_3 and X_5 are N and not more than 1 of X_3 and X_5 are S;

R_1 is hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

R_2 is an aryl, heteroaryl or non-aromatic heterocyclyl group G_1, which group G_1 is optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group, consisting of cyano, amino, amino-(C_{1-8})alkyl, *N*-(C_{1-4})alkyl-amino-(C_{1-8})alkyl, *N,N*-di(C_{1-4})alkyl-amino-(C_{1-8})alkyl, aminocarbonyl, thiocarbamoyl, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, hydroxy, oxo, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{3-8})cycloalkyl-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, (C_{2-8})alkynyl, (C_{2-8})alkenoxy, (C_{2-8})alkynoxy and a (C_{3-8})cycloalkyl, aryl, heteroaryl or non-aromatic heterocyclyl group G_2, which group G_2 is

optionally substituted by 1, 2, 3, or 4 substituents independently selected from the group, consisting of cyano, aminocarbonyl, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, hydroxy, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl and (C_{2-8})alkynyl;

R_3 is hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy; halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

R_4 is hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

R_5 is hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

or

R_4 and R_5, taken together, are -C(H)=C(H)-C(H)=C(H)- or a (C_{1-8})alkylene group, in which (C_{1-8})alkylene group 1 or 2 $-CH_2-$ ring members are optionally replaced with hetero ring members independently selected from the group, consisting of -N(H)-, -N[(C_{1-8})alkyl]-, -O-, -S-, -S(=O)- or $-S(=O)_2-$;

R_6 is (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, hydroxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkyl, mercapto-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkyl, amino-(C_{1-8})alkyl, *N*-(C_{1-4})alkyl-amino-(C_{1-8})alkyl, *N,N*-di(C_{1-4})alkyl-amino-(C_{1-8})alkyl, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

or

R_5 and R_6, taken together, are a (C_{1-4})alkylene group, in which (C_{1-4})alkylene group 1 $-CH_2-$ ring member is optionally replaced with a hetero ring member independently selected from the group, consisting of -N(H)-, -N[(C_{1-4})alkyl]-, -O-, -S-, -S(=O)- or $-S(=O)_2-$;

E_1 is $-C(R_7)(R_8)-$, or $-C(R_7)(R_8)-C(R_9)(R_{10})-$;

E_2 is $-C(R_{11})(R_{12})-$, or $-C(R_{11})(R_{12})-C(R_{13})(R_{14})-$;

either

each of R_7 and R_8 is independently selected from the group, consisting of hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkyl and (C_{1-8})alkylthio-(C_{1-8})alkyl;

or

R_7 and R_8, taken together, are oxo or $-CH_2-CH_2-$;

either

each of R_9 and R_{10} is independently selected from the group, consisting of hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkyl and (C_{1-8})alkylthio-(C_{1-8})alkyl;

or

R_9 and R_{10}, taken together, are oxo or $-CH_2-CH_2-$;

either

each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkyl and (C_{1-8})alkylthio-(C_{1-8})alkyl;

or

R_{11} and R_{12}, taken together, are oxo or $-CR_{15}R_{16}-CR_{17}R_{18}-$

wherein R_{15}, R_{16}, R_{17} and R_{18} are independently selected from hydrogen and fluoro;

and

either

each of R_{13} and R_{14} is independently selected from the group, consisting of hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkyl and (C_{1-8})alkylthio-(C_{1-8})alkyl;

or

R_{13} and R_{14}, taken together, are oxo or $-CH_2-CH_2-$.

2. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R_1 is hydrogen.

3. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R_2 is a 5- or 6-membered heteroaryl group in which structure 1, 2, 3, or 4 ring members are hetero ring members independently selected from the group consisiting of a nitrogen ring member, an oxygen ring member and a sulfur ring member, which group is optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group, consisting of cyano, amino, aminocarbonyl, thiocarbamoyl, halogen, (C_{1-4})alkyl, halogen-(C_{1-4})alkyl, hydroxy, oxo, (C_{1-4})alkoxy, halogen-(C_{1-4})alkoxy, (C_{1-4})alkylthio, halogen-(C_{1-4})alkylthio, (C_{1-4})alkoxy-(C_{1-4})alkyl, (C_{1-4})alkoxy-(C_{1-4})alkoxy, (C_{1-4})alkoxy-(C_{1-4})alkylthio, (C_{1-4})alkylthio-(C_{1-4})alkyl, (C_{1-4})alkylthio-(C_{1-4})alkoxy, (C_{1-4})alkylthio-(C_{1-4})alkylthio, (C_{2-4})alkenyl, (C_{2-4})alkynyl, (C_{2-4})alkenoxy, and (C_{2-4})alkynoxy.

4. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R_3 is hydrogen.

5. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

X_1 is CH or N;

X_3 is CH or N;

X_4 is CR_4 or N;

X_5 is CR_5;

wherein one and not more than one of X_1, X_3 and X_4 is N;.

6. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R_4 is hydrogen, or halogen; and R_5 is hydrogen, or halogen.

7. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R_6 is (C_{1-3})alkyl, or halogen-(C_{1-3})alkyl.

8. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein E_1 is $-C(R_7)(R_8)-$ and

either

each of R_7 and R_8 is hydrogen;

or

R_7 and R_8, taken together, are oxo.

9. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein E_2 is $-C(R_{11})(R_{12})-$ and

either

each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, (C_{1-3})alkyl and halogen-(C_{1-3})alkyl;

or

R_{11} and R_{12}, taken together, are oxo.

10. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

5-Bromo-pyridine-2-carboxylic acid [6-(5-amino-3-methyl-3,6-dihydro-2H-[1,4]-oxazin-3-yl)-pyridin-2-yl]-amide;

5-Chloro-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Bromo-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
4,6-Dideutero-5-chloro-3-trideuteromethyl-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Thiocarbamoyl-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoro-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
4,6-Dideutero-5-chloro-3-trideuteromethyl-pyridine-2-carboxylic acid [4-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Chloro-pyridine-2-carboxylic acid [4-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [4-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Bromo-pyridine-2-carboxylic acid [5-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-6-chloro-pyridin-3-yl]-amide;
3-Amino-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Chloro-4,6-dideuterio-3-trideuteriomethyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Bromo-3-chloro-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Amino-5-(2,2,2-trifluoro-ethoxy)-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;

5-Methoxy-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-(2,2,2-trifluoro-ethoxy)-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

5-Difluoromethoxy-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Chloro-5-difluoromethoxy-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3,5-Dichloro-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

5-Fluoromethoxy-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

5-Methyl-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Chloro-5-cyano-pyridine-2-carboxylic acid [4-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;

3-Chloro-5-difluoromethoxy-pyridine-2-carboxylic acid [4-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;

5-Cyano-3-methyl-pyridine-2-carboxylic acid [4-(5-amino-6,6-bis-fluoromethyl-3-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;

5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3-difluoromethyl-3,6-dihydro-2H-[1,4] oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;

3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3-difluoromethyl-3,6-dihydro-2H-[1,4] oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;

3,5-Dimethyl-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-(3-fluoro-propoxy)-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-(2-methoxy-ethyl)-5H-pyrrolo[2,3-b]pyrazine-2-carboxylic acid [6-((5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-trifluoromethyl-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-(2,2-difluoro-ethyl)-5H-pyrrolo[2,3-b]pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
4-Chloro-1-difluoromethyl-1H-pyrazole-3-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
6-Chloro-1-(2,2-difluoro-ethyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide; and
6-Chloro-1-(2-methoxy-ethyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide.

11. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for use as a medicament.

12. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of Alzheimer's disease or mild cognitive impairment.

13. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of insulin resistance, glucose intolerance, type 2 diabetes, obesity, hypertension, or diabetic complications.

14. A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, as active pharmaceutical ingredient in association with at least one pharmaceutically acceptable carrier or diluent.


15. The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of Alzheimer's disease or mild cognitive impairment.

16. The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of insulin resistance, glucose intolerance, type 2 diabetes, obesity, hypertension, or diabetic complications.

17. A pharmaceutical combination comprising a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a second drug substance, for simultaneous or sequential administration.

CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,



(I),

in which

X_1 is CR_1 or N;

X_3 is CR_3 or N;

X_4 is CR_4 or N;

X_5 is CR_5;

wherein one and not more than one of X_1, X_3 and X_4 is N;

R_1 is hydrogen;

R_2 is an aryl, heteroaryl or non-aromatic heterocyclyl group G_1, which group G_1 is optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group, consisting of cyano, amino, amino-(C_{1-8})alkyl, *N*-(C_{1-4})alkyl-amino-(C_{1-8})alkyl, *N,N*-di(C_{1-4})alkyl-amino-(C_{1-8})alkyl, aminocarbonyl, thiocarbamoyl, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, hydroxy, oxo, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{3-8})cycloalkyl-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, (C_{2-8})alkynyl, (C_{2-8})alkenoxy, (C_{2-8})alkynoxy and a (C_{3-8})cycloalkyl, aryl, heteroaryl or non-aromatic heterocyclyl group G_2, which group G_2 is optionally substituted by 1, 2, 3, or 4 substituents independently selected from the group, consisting of cyano, aminocarbonyl, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, hydroxy, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl and (C_{2-8})alkynyl;

R_3 is hydrogen;

R_4 is hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

R_5 is hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy, halogen-(C_{1-8})alkoxy, (C_{1-8})alkylthio, halogen-(C_{1-8})alkylthio, (C_{1-8})alkoxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkoxy, (C_{1-8})alkoxy-(C_{1-8})alkylthio, (C_{1-8})alkylthio-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkoxy, (C_{1-8})alkylthio-(C_{1-8})alkylthio, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

or

R_4 and R_5, taken together, are -C(H)=C(H)-C(H)=C(H)- or a (C_{1-8})alkylene group, in which (C_{1-8})alkylene group 1 or 2 $-CH_2-$ ring members are optionally replaced with hetero ring members independently selected from the group, consisting of -N(H)-, -N[(C_{1-8})alkyl]-, -O-, -S-, -S(=O)- or $-S(=O)_2-$;

R_6 is (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, hydroxy-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkyl, mercapto-(C_{1-8})alkyl, (C_{1-8})alkylthio-(C_{1-8})alkyl, amino-(C_{1-8})alkyl, *N*-(C_{1-4})alkyl-amino-(C_{1-8})alkyl, *N,N*-di(C_{1-4})alkyl-amino-(C_{1-8})alkyl, (C_{2-8})alkenyl, or (C_{2-8})alkynyl;

or

R_5 and R_6, taken together, are a (C_{1-4})alkylene group, in which (C_{1-4})alkylene group 1 $-CH_2-$ ring member is optionally replaced with a hetero ring member independently selected from the group, consisting of -N(H)-, -N[(C_{1-4})alkyl]-, -O-, -S-, -S(=O)- or $-S(=O)_2-$;

E_1 is $-C(R_7)(R_8)-$ wherein each of R_7 and R_8 is hydrogen;

E_2 is $-C(R_{11})(R_{12})-$;

either

each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, cyano, halogen, (C_{1-8})alkyl, halogen-(C_{1-8})alkyl, (C_{1-8})alkoxy-(C_{1-8})alkyl and (C_{1-8})alkylthio-(C_{1-8})alkyl;


or

R_{11} and R_{12}, taken together, are oxo or $-CR_{15}R_{16}-CR_{17}R_{18}-$

wherein R_{15}, R_{16}, R_{17} and R_{18} are independently selected from hydrogen and fluoro.

2. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein X_1 is N; X_3 is CR_3; X_4 is CR_4; and X_5 is CR_5.

3. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, of formula (Ic)



(Ic),

in which

X_1 is CH or N;

X_3 is CH or N;

X_4 is CR_4 or N;

wherein one and not more than one of X_1, X_3 and X_4 is N;


R_2 is a 5- or 6-membered heteroaryl group in which structure 1, 2, 3, or 4 ring members are hetero ring members independently selected from the group consisiting of a nitrogen ring member, an oxygen ring member and a sulfur ring member, which group is optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group, consisting of cyano, amino, aminocarbonyl, thiocarbamoyl, halogen, (C_{1-4})alkyl, halogen-(C_{1-4})alkyl, hydroxy, oxo, (C_{1-4})alkoxy, halogen-(C_{1-4})alkoxy, (C_{1-4})alkylthio, halogen-(C_{1-4})alkylthio, (C_{1-4})alkoxy-(C_{1-4})alkyl, (C_{1-4})alkoxy-(C_{1-4})alkoxy, (C_{1-4})alkoxy-(C_{1-4})alkylthio, (C_{1-4})alkylthio-(C_{1-4})alkyl, (C_{1-4})alkylthio-(C_{1-4})alkoxy, (C_{1-4})alkylthio-(C_{1-4})alkylthio, (C_{2-4})alkenyl, (C_{2-4})alkynyl, (C_{2-4})alkenoxy, and (C_{2-4})alkynoxy;

R_4 and R_5 are independently selected from the group consisting of hydrogen, cyano, halogen, (C_{1-4})alkyl, halogen-(C_{1-4})alkyl, (C_{1-4})alkoxy, or halogen-(C_{1-4})alkoxy;

R_6 is (C_{1-3})alkyl or fluoro-(C_{1-3})alkyl; and

each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, (C_{1-3})alkyl and halogen-(C_{1-3})alkyl.

4. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, of formula (Ic)



(Ic),

in which

X_1 is CH or N;

X_3 is CH or N;

X_4 is CR_4 or N;

wherein one and not more than one of X_1, X_3 and X_4 is N;

R_2 is a pyridyl or pyrazinyl group which is optionally substituted by 1, 2 or 3 substituents independently selected from the group, consisting of cyano, amino, aminocarbonyl, thiocarbamoyl, halogen, (C_{1-4})alkyl, halogen-(C_{1-4})alkyl, hydroxy, oxo, (C_{1-4})alkoxy, halogen-(C_{1-4})alkoxy, (C_{1-4})alkylthio, halogen-(C_{1-4})alkylthio, (C_{1-4})alkoxy-(C_{1-4})alkyl, (C_{1-4})alkoxy-(C_{1-4})alkoxy, (C_{1-4})alkoxy-(C_{1-4})alkylthio, (C_{1-4})alkylthio-(C_{1-4})alkyl, (C_{1-4})alkylthio-(C_{1-4})alkoxy, (C_{1-4})alkylthio-(C_{1-4})alkylthio, (C_{2-4})alkenyl, (C_{2-4})alkynyl, (C_{2-4})alkenoxy, and (C_{2-4})alkynoxy;

R_4 and R_5 are independently hydrogen, or halogen;


R_6 is (C_{1-3})alkyl or fluoro-(C_{1-3})alkyl; and

each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, (C_{1-3})alkyl and fluoro-(C_{1-3})alkyl.

5. A compound according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, methyl, fluoromethyl, difluoromethyl and trifluoromethyl.

6. A compound according to any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R_6 is methyl, fluoromethyl, difluoromethyl or trifluoromethyl.

7. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, of formula (Id)



(Id),

in which

X_1 is CH or N;

X_3 is CH or N;

X_4 is CR_4 or N;

wherein one and not more than one of X_1, X_3 and X_4 is N;

R_2 is a pyridyl or pyrazinyl group which is substituted by 2 or 3 substituents and wherein one of the substituents is located at the *para* position and one of the substituents is located at the *ortho* position of the pyridyl or pyrazinyl group relative to the amide linker and wherein the substituents are independently selected from the group, consisting of cyano, amino, halogen, (C_{1-4})alkyl, halogen-(C_{1-4})alkyl, hydroxy, oxo, (C_{1-4})alkoxy and halogen-(C_{1-4})alkoxy;

R_4 and R_5 are independently hydrogen, or halogen;

R_6 is methyl, fluoromethyl, difluoromethyl or trifluoromethyl; and

each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, methyl, fluoromethyl, difluoromethyl and trifluoromethyl.


8. A compound according to any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R_2 is a pyridin-2-yl or pyrazin-2-yl group which is substituted by 2 substituents and wherein one of the substituents is located at the *para* position and one of the substituents is located at the *ortho* position of the pyridin-2-yl or pyrazin-2-yl group relative to the amide linker and wherein the substituents are independently selected from the

group, consisting of cyano, amino, fluoro, bromo, chloro, hydroxyl, oxo, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and trifluromethoxy.

9. A compound according to any one of Claims 3 to 8, or a pharmaceutically acceptable salt thereof, wherein X_1 is N; X_3 is CH; and X_4 is CR_4.

10. A compound according to any one of Claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R_4 is hydrogen.

11. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, of formula (Ie)



(Ie),

in which

R_2 is a pyridin-2-yl or pyrazin-2-yl group which is substituted by 2 substituents and wherein one of the substituents is located at the *para* position and one of the substituents is located at the *ortho* position of the pyridin-2-yl or pyrazin-2-yl group relative to the amide linker and wherein the substituents are independently selected from the group, consisting of cyano, amino, fluoro, bromo, chloro, hydroxyl, oxo, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and trifluromethoxy;

R_5 is hydrogen or fluoro;

R_6 is methyl, fluoromethyl or difluoromethyl; and

each of R_{11} and R_{12} is independently selected from the group, consisting of hydrogen, methyl, fluoromethyl, difluoromethyl and trifluoromethyl.

12. A compound according to any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R_5 is fluoro.

13. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

5-Bromo-pyridine-2-carboxylic acid [6-(5-amino-3-methyl-3,6-dihydro-2H-[1,4]-oxazin-3-yl)-pyridin-2-yl]-amide;

5-Chloro-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;

5-Bromo-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
4,6-Dideutero-5-chloro-3-trideuteromethyl-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Thiocarbamoyl-pyridine-2-carboxylic acid [6-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoro-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
4,6-Dideutero-5-chloro-3-trideuteromethyl-pyridine-2-carboxylic acid [4-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Chloro-pyridine-2-carboxylic acid [4-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [4-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Bromo-pyridine-2-carboxylic acid [5-(5-amino-3-fluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-6-chloro-pyridin-3-yl]-amide;
3-Amino-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Chloro-4,6-dideuterio-3-trideuteriomethyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Bromo-3-chloro-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Amino-5-(2,2,2-trifluoro-ethoxy)-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Methoxy-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-(2,2,2-trifluoro-ethoxy)-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
5-Difluoromethoxy-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Chloro-5-difluoromethoxy-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3,5-Dichloro-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
5-Fluoromethoxy-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
5-Methyl-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [4-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
3-Chloro-5-difluoromethoxy-pyridine-2-carboxylic acid [4-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [4-(5-amino-6,6-bis-fluoromethyl-3-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-(5-amino-3-difluoromethyl-3,6-dihydro-2H-[1,4] oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-(5-amino-3-difluoromethyl-3,6-dihydro-2H-[1,4] oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
3,5-Dimethyl-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-(3-fluoro-propoxy)-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-(2-methoxy-ethyl)-5H-pyrrolo[2,3-b]pyrazine-2-carboxylic acid [6-((5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-trifluoromethyl-pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-(2,2-difluoro-ethyl)-5H-pyrrolo[2,3-b]pyrazine-2-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;


4-Chloro-1-difluoromethyl-1H-pyrazole-3-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
6-Chloro-1-(2,2-difluoro-ethyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide; and
6-Chloro-1-(2-methoxy-ethyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid [6-(5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide.

14. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:
5-Bromo-pyridine-2-carboxylic acid [6-((R)-5-amino-3-methyl-3,6-dihydro-2H-[1,4]-oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoro-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-pyridine-2-carboxylic acid [6-((3S,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-((3S,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [4-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [4-((3S,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
3-Amino-5-cyano-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Chloro-4,6-dideuterio-3-trideuteriomethyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
5-Bromo-3-chloro-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Amino-5-(2,2,2-trifluoro-ethoxy)-pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-((3R, 6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Methoxy-3-methyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;


3-Amino-5-(2,2,2-trifluoro-ethoxy)-pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-cyano-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-((3S,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
5-Difluoromethoxy-3-methyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Chloro-5-difluoromethoxy-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3,5-Dichloro-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
5-Fluoromethoxy-3-methyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
5-Methyl-pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [4-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
3-Chloro-5-difluoromethoxy-pyridine-2-carboxylic acid [4-((3S,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [4-((R)-5-amino-6,6-bis-fluoromethyl-3-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-((R)-5-amino-3-difluoromethyl-3,6-dihydro-2H-[1,4] oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
5-Cyano-3-methyl-pyridine-2-carboxylic acid [6-((S)-5-amino-3-difluoromethyl-3,6-dihydro-2H-[1,4] oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
3-Chloro-5-cyano-pyridine-2-carboxylic acid [6-((R)-5-amino-3-difluoromethyl-3,6-dihydro-2H-[1,4] oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
3,5-Dimethyl-pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-(3-fluoro-propoxy)-pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;
3-Amino-5-(2-methoxy-ethyl)-5H-pyrrolo[2,3-b]pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide;

3-Amino-5-(2,2-difluoro-ethyl)-5H-pyrrolo[2,3-b]pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
4-Chloro-1-difluoromethyl-1H-pyrazole-3-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide;
6-Chloro-1-(2,2-difluoro-ethyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide; and
6-Chloro-1-(2-methoxy-ethyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide.


15. A compound according to Claim 1 which is 5-cyano-3-methyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]-amide, or a pharmaceutically acceptable salt thereof, having the following formula



16. A compound according to Claim 1 which is 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide, or a pharmaceutically acceptable salt thereof, having the following formula



17. A compound according to Claim 1 which is 3-amino-5-trifluoromethyl-pyrazine-2-carboxylic acid [6-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-5-fluoro-pyridin-2-yl]amide, or a pharmaceutically acceptable salt thereof, having the following formula



18. A compound according to any one of Claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use as a medicament.

19. A compound according to any one of Claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of Alzheimer's disease or mild cognitive impairment.

20. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 17, or a pharmaceutically acceptable salt thereof, as active pharmaceutical ingredient in association with at least one pharmaceutically acceptable carrier or diluent.

21. A pharmaceutical combination comprising a therapeutically effective amount of a compound according to any one of Claims 1 to 17, or a pharmaceutically acceptable salt thereof, and a second drug substance, for simultaneous or sequential administration.